Durect Corp
(FRA:DC8A)
€
0.785
-0.015 (-1.88%)
Market Cap: 25.87 Mil
Enterprise Value: 29.05 Mil
PE Ratio: 0
PB Ratio: 22.56
GF Score: 60/100 DURECT Corp at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023 / 02:00PM GMT
Release Date Price:
€3.74
(-2.60%)
Ed Arce
H. C. Wainwright & Co., LLC - Analyst
Great. Welcome, everyone. And our next presenting company is DURECT. I'm very pleased to have with us members of the senior management team. To my right is CEO, Jim Brown; and to my left is CFO, Tim Papp. Jim, Tim, thank you so much for joining us.
Tim Papp
DURECT Corporation - CFO
Thank you, Ed.
Jim Brown
DURECT Corporation - President & CEO
Thanks, Ed. It's great to see you.
Ed Arce
H. C. Wainwright & Co., LLC - Analyst
Yeah. So I wanted to start by just asking if you could provide a brief overview of the company and the current status of both your marketed and development programs.
Jim Brown
DURECT Corporation - President & CEO
Sure. Now, we -- as a company, we are focused on developing products that regulate the epigenome. And we have a history of once upon a time, we started as a company and especially the pharma space with drug delivery.
So we
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot